PHASE 3 TRIAL TEAM-ET IN 106 HIGH-RISK ESSENTIAL THROMBOCYTHEMIA PATIENTS, DEMONSTRATING NON-INFERIORITY OF ANATHROMB, A NOVEL, EXTENDED-RELEASE ANAGRELIDE FORMULATION, TO THE LICENSED COMPARATOR
		        
		        	EHA Library, Heinz Gisslinger, 
		        			                133284
		            		       
		    
				
			
		        PHASE II STUDY OF LCL161, A SMAC MIMETIC, IN PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MYELOFIBROSIS (POST-PV MF) OR POST-ESSENTIAL THROMBOCYTOSIS MYELOFIBROSIS (POST-ET MF
		        
		        	EHA Library, Naveen Pemmaraju, 
		        			                133287
		            		       
		    
				
			
		        PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF GBT440, A NOVEL HEMOGLOBIN S (HBS) POLYMERIZATION INHIBITOR FOR THE TREATMENT OF SICKLE CELL DISEASE (SCD), IN HEALTHY VOLUNTEERS AND SCD PATIENTS
		        
		        	EHA Library, Mira Pochron, 
		        			                133357
		            		       
		    
				
			
		        SAFETY AND EFFICACY OF RUXOLITINIB IN PATIENTS WITH DIPSS INTERMEDIATE-1–RISK MYELOFIBROSIS (MF) FROM JUMP: AN OPEN-LABEL, MULTICENTER, SINGLE-ARM, EXPANDED-ACCESS STUDY
		        
		        	EHA Library, Francesco Passamonti, 
		        			                133283
		            		       
		    
				
			
		        OUTCOMES AFTER AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION (SCT) IN DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) PATIENTS WITH MYC/BCL2 CO-EXPRESSION, DOUBLE-HIT LYMPHOMA, OR MYC COPY GAIN
		        
		        	EHA Library, Alex F. Herrera, 
		        			                133327
		            		       
		    
				
			
		        MULTICENTER, PROSPECTIVE, RANDOMIZED TRIAL OF INTRAVENOUS ITRACONAZOLE VS. LIPOSOMAL AMPHOTERICIN B AS EMPIRICAL ANTIFUNGAL THERAPY FOR HEMATOLOGICAL MALIGNANCY WITH PERSISTENT FEVER AND NEUTROPENIA
		        
		        	EHA Library, Isao Yoshida, 
		        			                133365